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Yellow fever (YF) is an acute viral hemorrhagic disease endemic in tropical areas of Africa, Central and South 
America, which is transmitted by the bite of infected mosquitoes. It is a “historically devastating disease” (Paules 
and Fauci, 2017) that killed during outbreaks in past centuries, before the introduction of the current vaccine, 
approximately 10% of the population of cities like Philadelphia (USA) and Barcelona (Spain). According to 
Garske et al. (2014), YF caused in 2013 78,000 deaths worldwide, which is a disease burden comparable to 
influenza. In the past few years, outbreaks in Angola (2016) and in Brazil (2017-2018) led to the depletion of the 
WHO vaccine stockpile and to the introduction of the emergency use of a fractional dose (1/5). Furthermore, the 
Angola outbreak in 2016 caused the first cases of YF ever to occur in Asia (11 imported cases to China), rising 
the concern about approximately 2 billion immunologically naïve people who would be at high risk in Asia in 
case local transmission of the virus starts to occur (Wilder-Smith et al., 2019).  
 
The urgent need for a new YF vaccine becomes evident from two major issues concerning the current vaccine, 
which consists of a live-attenuated virus propagated in chicken embryos: (i) vaccine shortage due to limitations 
in the manufacturing technology; (ii) rare, but fatal adverse effects. Therefore, this work focuses on the 
development of a safe, non-replicating YF vaccine, produced by a high-productivity perfusion process. 
 
Stable recombinant HEK293 cell lines constitutively expressing the structural proteins prM (pre-membrane) and 
E (envelope) of YFV were generated, enabling long-term production and secretion of recombinant virus-like 
particles (VLPs). FACS (fluorescence activated cell sorting) was used to sort the transfected population for high 
producer cells and allowed obtaining an enriched cell pool producing significantly higher amounts of VLPs. 
Small scale kinetic studies under intermittent perfusion (pseudoperfusion) were performed in order to investigate 
possible feeding strategies and to evaluate the use of short-chain fatty acids as productivity enhancers. 
Subsequently, perfusion runs were carried out in stirred-tank bioreactors in order to investigate optimal 
conditions for VLP production, as well as to evaluate different cell retention devices (e.g. inclined lamella settler 
and ATF-2). Partial retention of the VLPs in the perfusion bioreactor system occurred when the ATF-2 was 
used. VLPs produced by perfusion were purified by a two-step chromatographic process, and transmission 
electron microscopy (TEM) images confirmed the expected size and morphology of the VLPs, enabling their use 
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